View in EDS

An open-label phase 1 trial of the safety and efficacy of daily subcutaneous spl-108 injections in combination with paclitaxel in patients with platinum-resistant, CD44+, advanced ovarian epithelial cancer.

Saved in:
Bibliographic Details
Title: An open-label phase 1 trial of the safety and efficacy of daily subcutaneous spl-108 injections in combination with paclitaxel in patients with platinum-resistant, CD44+, advanced ovarian epithelial cancer.
Authors: Girda, E.1 (AUTHOR), De Meritens, A. Buckley1 (AUTHOR), Leiser, A.1 (AUTHOR), Stephenson, R.D.1 (AUTHOR), Nelson, D.1 (AUTHOR), Rodriguez-Rodriguez, L.1 (AUTHOR)
Source: Gynecologic Oncology. Jul2019:Supplement 1, Vol. 154, p93-93. 1p.
Database: Academic Search Ultimate
Description
ISSN:00908258
DOI:10.1016/j.ygyno.2019.04.218